Altamira Therapeutics Ltd. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form F-3 effective as of January 19, 2024, at 5:00 P.M. This form is a registration statement that pertains to the offering of securities in the U.S. The effectiveness of this form indicates that Altamira Therapeutics has met all the necessary regulatory requirements to proceed with the securities offering. The SEC's notice of effectiveness is a standard procedure that allows the company to issue securities to the public, which could potentially lead to an increase in capital for future endeavors.

Altamira Therapeutics Ltd. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form F-3 effective as of January 19, 2024, at 5:00 P.M. This form is a registration statement that pertains to the offering of securities in the U.S. The effectiveness of this form indicates that Altamira Therapeutics has met all the necessary regulatory requirements to proceed with the securities offering. The SEC's notice of effectiveness is a standard procedure that allows the company to issue securities to the public, which could potentially lead to an increase in capital for future endeavors.